Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
